What is cerliponase alfa used for?
Cerliponase alfa (brand name Brineura) is used to treat patients with CLN2 disease (a form of neuronal ceroid lipofuscinosis, NCL), a rare, inherited neurodegenerative disorder. It is designed to slow disease progression by targeting the defective disease process in the brain for people with the condition indicated for treatment [1].
How is cerliponase alfa given?
Cerliponase alfa is administered by intraventricular infusion, meaning it is delivered directly into the brain’s ventricular system through a surgically placed device [1].
How often is it given?
Treatment is given on a regular schedule (maintenance dosing), with infusions repeated repeatedly over time as part of ongoing therapy for CLN2 disease [1].
Who should use it, and are there age restrictions?
Cerliponase alfa is indicated for certain patients with CLN2 disease. The specific eligible patient population (including age and disease stage criteria) is defined in the prescribing information/label for Brineura [1].
What are the main side effects patients and families ask about?
Common risks reported for intraventricular therapies include infusion-related reactions and complications related to the infusion procedure. The Brineura prescribing information lists the adverse reactions observed with treatment [1].
What makes cerliponase alfa different from other treatments for NCL?
Because cerliponase alfa is delivered directly into the brain and is formulated for CLN2 disease, it is used specifically for that NCL subtype rather than being a general therapy for all forms of neuronal ceroid lipofuscinosis [1].
How is it monitored during treatment?
Patients receiving cerliponase alfa typically require ongoing clinical monitoring to track neurologic function and to watch for adverse reactions related to intraventricular infusion and the implanted delivery system, as described in the product labeling and treatment protocol [1].
Where can I find the official dosing and safety details?
The most reliable source is the official prescribing information for Brineura (cerliponase alfa), which contains the exact indication language, dosing schedule, contraindications (if any), warnings/precautions, and adverse reactions [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/###